1. Extending expressed RNA genomics from surgical decision making for cytologically indeterminate thyroid nodules to targeting therapies for metastatic thyroid cancer
- Author
-
Syed Z. Ali, Paul W. Ladenson, Giulia C. Kennedy, Allan C. Golding, Richard T. Kloos, Allan Siperstein, and Peter M. Sadow
- Subjects
Thyroid nodules ,Oncology ,endocrine system ,Cancer Research ,medicine.medical_specialty ,Biopsy, Fine-Needle ,Clinical Decision-Making ,Thyroid Gland ,indeterminate cytology ,030209 endocrinology & metabolism ,Genomics ,Malignancy ,molecular diagnostics ,Diagnosis, Differential ,Machine Learning ,Transcriptome ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Adenocarcinoma, Follicular ,Biomarkers, Tumor ,Humans ,Medicine ,RNA, Messenger ,RNA, Neoplasm ,RNA-Seq ,Thyroid Neoplasms ,Precision Medicine ,business.industry ,Thyroid ,Molecular diagnostics ,medicine.disease ,Gene Expression Regulation, Neoplastic ,medicine.anatomical_structure ,Thyroid Cancer, Papillary ,030220 oncology & carcinogenesis ,thyroid nodule ,Commentary ,Thyroidectomy ,Feasibility Studies ,Reagent Kits, Diagnostic ,Sample collection ,business ,Indeterminate ,clinical validation - Abstract
The Afirma Genomic Sequencing Classifier (GSC) is a rule‐out test for malignancy/noninvasive follicular thyroid neoplasms with papillary‐like nuclear features among patients with Bethesda category III/IV nodules, whereas the complimentary Xpression Atlas provides genomic insights from a curated panel of 511 genes among GSC suspicious and Bethesda category V/VI nodules. Together, they facilitate personalized treatment decisions based on genomic insights derived from the transcriptome of the biopsied target and extend the diagnostic and therapeutic reach of cytopathologists and fine‐needle aspiration biopsy sample collection.
- Published
- 2019
- Full Text
- View/download PDF